Academic Journal
Targeting YES1 enhances the efficacy of chemotherapy, targeted therapy and onco-immunotherapy.
| Τίτλος: | Targeting YES1 enhances the efficacy of chemotherapy, targeted therapy and onco-immunotherapy. |
|---|---|
| Συγγραφείς: | Zheng D; School of Pharmacy, North China University of Science and Technology, 21 Bohai Road, Caofeidian District, Tangshan, China., Wang Y; School of Pharmacy, North China University of Science and Technology, 21 Bohai Road, Caofeidian District, Tangshan, China., Li J; Teaching and Experiment Center, Liaoning University of Traditional Chinese Medicine, Shenyang, China., Zhang G; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA., Chu E; Department of Oncology and Cancer Therapeutics Program, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY, USA. Electronic address: edward.chu@einsteinmed.edu., Wei N; Department of Oncology and Cancer Therapeutics Program, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY, USA. Electronic address: ning.wei@einsteinmed.edu. |
| Πηγή: | Cellular signalling [Cell Signal] 2025 Dec; Vol. 136, pp. 112108. Date of Electronic Publication: 2025 Sep 02. |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 8904683 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3913 (Electronic) Linking ISSN: 08986568 NLM ISO Abbreviation: Cell Signal Subsets: MEDLINE |
| Imprint Name(s): | Publication: Oxford : Elsevier Science Ltd Original Publication: Oxford ; New York : Pergamon Press, 1988- |
| Ιατρικοί όροι (MeSH): | Neoplasms*/therapy , Neoplasms*/drug therapy , Neoplasms*/immunology , Immunotherapy*/methods , Proto-Oncogene Proteins c-yes*/antagonists & inhibitors , Proto-Oncogene Proteins c-yes*/metabolism , Antineoplastic Agents*/therapeutic use , Antineoplastic Agents*/pharmacology , Molecular Targeted Therapy*, Tumor Microenvironment/drug effects ; Drug Resistance, Neoplasm/drug effects ; Protein Kinase Inhibitors/therapeutic use ; Signal Transduction/drug effects ; Humans ; Animals |
| Περίληψη: | YES1 (Yamaguchi sarcoma virus homolog 1), a non-receptor tyrosine kinase of the SRC family (SFK), has been abnormally amplified or mutated in several types of solid tumors. The alteration of YES1 impacted multiple biological processes, including promoting tumor progression and metastasis, especially, producing cancer therapy resistance via bypass pathways. Thus, YES1 can serve as a druggable target to overcome drug resistance and suppress tumor growth. Due to toxicity and lack of selectivity, several SFK-targeted agents in clinical trials were limited for further investigation. Recently, the emerging role of YES1-selective inhibitors and the promising approach of combinational therapy have exhibited synergistic anti-tumor effects. Herein, we summarize the multiple mechanisms of YES1-driving tumor progression and resistance, focusing on YES1 inhibitors in combination with other therapies. We also discuss the oncogenic mechanism of the YES1-YAP1 pathway, EGFR-YES1 crosstalk, the roles of YES1 in the tumor microenvironment, and the synthetic lethal effect of YES1 inhibitors. Taken together, available evidences strongly suggest that targeting YES1 could be a promising sensitization strategy for cancer treatment and improve the patient's quality of life. (Copyright © 2025 Elsevier Inc. All rights reserved.) |
| Competing Interests: | Declaration of competing interest The authors declare no competing interests. |
| Contributed Indexing: | Keywords: Chemotherapy; Drug resistance; Non-receptor tyrosine kinase; Onco-immunotherapy; YES1 inhibitors |
| Substance Nomenclature: | EC 2.7.10.2 (Proto-Oncogene Proteins c-yes) EC 2.7.10.2 (YES1 protein, human) 0 (Antineoplastic Agents) 0 (Protein Kinase Inhibitors) |
| Entry Date(s): | Date Created: 20250904 Date Completed: 20251113 Latest Revision: 20251114 |
| Update Code: | 20260130 |
| DOI: | 10.1016/j.cellsig.2025.112108 |
| PMID: | 40907631 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1873-3913 |
|---|---|
| DOI: | 10.1016/j.cellsig.2025.112108 |